The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Kura Oncology
Stock and Other Ownership Interests - Kinnate Biopharma; Primmune Therapeutics
Consulting or Advisory Role - Cel-Sci; Hookipa Biotech; ImmunoSensor; ISTARI Oncology; Mana Therapeutics; Nectin Tx; Pangea
Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC).
 
Jonathan W. Riess
Consulting or Advisory Role - BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Novartis; Regeneron; Teladoc; Turning Point Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
 
Paul Shaw
Honoraria - Takeda
Consulting or Advisory Role - Takeda
Speakers' Bureau - AstraZeneca
 
Devraj Srinivasan
Honoraria - BMS
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Soligenix (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Pilar Garrido
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim (I); Bristol-Myers Squibb; Gebro Pharma (I); GlaxoSmithKline; Janssen Biotech (I); Janssen Oncology; Lilly; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Takeda
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Jacqueline Vuky
Research Funding - Agendia (Inst); Arvinas (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); Exelixis (Inst); Fortis (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Rgenix (Inst)
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Shane O'Neill
Employment - Autolus; IO Biotech
Stock and Other Ownership Interests - Amgen; Autolus; IO Biotech
Travel, Accommodations, Expenses - IO Biotech
 
Alireza Alavi
Employment - IO Biotech
Stock and Other Ownership Interests - IO Biotech
 
Diane Opatt McDowell
Employment - Bristol-Myers Squibb; IO Biotech
Leadership - IO Biotech
Stock and Other Ownership Interests - Bristol-Myers Squibb; IO Biotech
 
Eva Ehrnrooth
Employment - IO Biotech
Leadership - IO Biotech
Stock and Other Ownership Interests - IO Biotech
 
Ezra Cohen
No Relationships to Disclose